{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444653764
| IUPAC_name = 10-(3-dimethylamino-2-methyl-propyl)phenothiazine-2-carbonitrile
| image = Cyamemazine.svg

<!--Clinical data-->
| tradename = Tercian
| Drugs.com = {{drugs.com|international|cyamemazine}}
| pregnancy_category =  
| legal_status = Rx-Only
| routes_of_administration = Oral, IM, IV

<!--Pharmacokinetic data-->
| bioavailability = 10-70%
| protein_bound =  
| metabolism = Hepatic
| elimination_half-life = 10 hours
| excretion = Urine

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 3546-03-0
| ATC_prefix = N05
| ATC_suffix = AA06
| PubChem = 62865
| IUPHAR_ligand = 84
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB09000
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2104153
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 56597
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = A2JGV5CNU4
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07307

<!--Chemical data-->
| C=19 | H=21 | N=3 | S=1
| molecular_weight = 323.46 g/mol
| smiles = N#Cc2cc1N(c3c(Sc1cc2)cccc3)CC(C)CN(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H21N3S/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SLFGIOIONGJGRT-UHFFFAOYSA-N
}}

'''Cyamemazine''' ('''Tercian'''), also known as '''cyamepromazine''', is a [[typical antipsychotic]] [[drug]] of the [[phenothiazine]] [[chemical class|class]] which was introduced by [[Theraplix]] in [[France]] in 1972 and later in [[Portugal]] as well.<ref name="urlIndex nominum, international drug ... - Google Books">{{cite book | url = https://books.google.com/books?id=5GpcTQD_L2oC&lpg=PA280&dq=cyamemazine%20tercian&as_brr=3&pg=PA280#v=onepage&q=&f=false | title = Index nominum, international drug ... - Google Books | format = | work = | accessdate = }}</ref><ref name="isbn0-412-46630-9">{{cite book | author = David J. Triggle | title = Dictionary of Pharmacological Agents | publisher = Chapman & Hall/CRC | location = Boca Raton | year = 1996 | page = 534 | isbn = 0-412-46630-9 | oclc = | doi = | url = https://books.google.com/books?id=DeX7jgInYFMC&lpg=RA1-PA534&as_brr=3&pg=RA1-PA534#v=onepage&q=&f=false}}</ref><ref name="urlPharmaceutical manufacturing ... - Google Books">{{cite book | url = https://books.google.com/books?id=X2EyLsG4bcUC&lpg=PA397&dq=cyamemazine%20introduced&as_brr=3&pg=PA397#v=onepage&q=&f=false | title = Pharmaceutical manufacturing ... - Google Books | format = | work = | accessdate = }}</ref><ref name="pmid19393381">{{cite journal | vauthors = Bret P, Bret MC, Queuille E | title = [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals] | language = French | journal = L'Encéphale | volume = 35 | issue = 2 | pages = 129–38 |date=April 2009 | pmid = 19393381 | doi = 10.1016/j.encep.2008.03.007 | url = http://www.masson.fr/masson/S0013-7006(08)00103-6}}</ref> It is used for the treatment of [[schizophrenia]] and, especially, for [[psychosis]]-associated [[anxiety]], due to its unique [[anxiolytic]] efficacy.<ref name="urlStahls Essential Psychopharmacology - Cambridge University Press">{{cite web | url = http://stahlonline.cambridge.org/prescribers_drug.jsf?page=0521683505c20_p115-120.html.therapeutics&name=Cyamemazine | title = Stahl's Essential Psychopharmacology - Cambridge University Press | format = | work = | accessdate = }}</ref><ref name="pmid11423169">{{cite journal | vauthors = Bourin M, Nic Dhonnchadha BA, Claude Colombel M, Dib M, Hascoët M | title = Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice | journal = Behavioural Brain Research | volume = 124 | issue = 1 | pages = 87–95 |date=September 2001 | pmid = 11423169 | doi = 10.1016/S0166-4328(01)00238-8| url = http://linkinghub.elsevier.com/retrieve/pii/S0166432801002388}}</ref>

Cyamemazine differs from other phenothiazine neuroleptics in that aside from the usual profile of [[dopamine receptor|dopamine]], [[Alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic]], [[H1 receptor|H<sub>1</sub>]], and [[muscarinic acetylcholine receptor|mACh receptor]] [[receptor antagonist|antagonism]],<ref name="pmid12527336">{{cite journal | vauthors = Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M | title = Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes | journal = [[Biochemical Pharmacology (journal)|Biochemical Pharmacology]] | volume = 65 | issue = 3 | pages = 435–40 |date=February 2003 | pmid = 12527336 | doi = 10.1016/S0006-2952(02)01515-0| url = http://linkinghub.elsevier.com/retrieve/pii/S0006295202015150}}</ref> it additionally produces potent blockade of several [[serotonin receptor]]s, including [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub>]], and [[5-HT7 receptor|5-HT<sub>7</sub>]].<ref name="pmid12527336"/><ref name="pmid10672635">{{cite journal | vauthors = Alvarez-Guerra M, d'Alché-Birée F, Wolf WA, Vargas F, Dib M, Garay RP | title = 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity | journal = Psychopharmacology | volume = 147 | issue = 4 | pages = 412–7 |date=January 2000 | pmid = 10672635 | doi = 10.1007/s002130050010| url = http://link.springer.de/link/service/journals/00213/bibs/0147004/01470412.htm}}</ref><ref name="pmid12421652">{{cite journal | vauthors = Alvarez-Guerra M, Hameg A, Bayle F, Dib M, Garay RP | title = 5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle | journal = European Journal of Pharmacology | volume = 454 | issue = 2-3 | pages = 235–9 |date=November 2002 | pmid = 12421652 | doi = 10.1016/S0014-2999(02)02489-5| url = http://linkinghub.elsevier.com/retrieve/pii/S0014299902024895}}</ref><ref name="pmid17936750">{{cite journal | vauthors = Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A | title = Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes | journal = European Journal of Pharmacology | volume = 578 | issue = 2-3 | pages = 142–7 |date=January 2008 | pmid = 17936750 | doi = 10.1016/j.ejphar.2007.09.025 | url = http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(07)01053-9}}</ref> These actions have been implicated in cyamemazine's anxiolytic effects (5-HT<sub>2C</sub>) and lack of [[extrapyramidal symptom|extrapyramidal]] [[side effect]]s (5-HT<sub>2A</sub>),<ref name="pmid12527336"/><ref name="pmid10672635"/> and despite being classified as a [[typical antipsychotic]], it actually behaves like an [[atypical antipsychotic]].<ref name="pmid12595954">{{cite journal | vauthors = Peinado J, Hameg A, Garay RP, Bayle F, Nuss P, Dib M | title = Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 367 | issue = 2 | pages = 134–9 |date=February 2003 | pmid = 12595954 | doi = 10.1007/s00210-002-0665-4 }}</ref>

==References==
{{Reflist|30em}}

{{Antipsychotics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Alpha-1 blockers]]
[[Category:Dopamine antagonists]]
[[Category:H1 receptor antagonists]]
[[Category:Muscarinic antagonists]]
[[Category:Nitriles]]
[[Category:Phenothiazines]]
[[Category:Serotonin antagonists]]
[[Category:Typical antipsychotics]]


{{nervous-system-drug-stub}}